Trial Profile

A Phase I Dose Escalation Study of NMS-1286937 Administered to Adult Patients With Advanced/Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Onvansertib (Primary)
Indications Carcinoma; Colon cancer; Colorectal cancer; Head and neck cancer; Leiomyosarcoma; Liposarcoma; Liver cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Periampullary cancer; Prostate cancer; Skin cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Nerviano Medical Sciences

Most Recent Events

20 Jul 2017 Results published in the Investigational New Drugs
25 May 2017 Data from this trial is being submitted for peer review publication by study investigators, as reported in a TrovaGene Media Release
25 May 2017 Results published in the TrovaGene Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com